Source: Virtual Congress 2020 – Severe asthma phenotypes and outcomes
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Eger (Amsterdam, Netherlands), J. Kroes (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Sont (Amsterdam, Netherlands), E. Bel (Amsterdam, Netherlands). Real world residual disease manifestations after 2-years anti-IL-5 treatment for severe asthma. 5041

Member's Comments

No comment yet.

Related content which might interest you: Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Real life benralizumab effect in patients with severe eosinophilic asthma after 16 weeks of observation Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Inflammatory biomarkers in the evaluation of two-year  outcomes  of omalizumab treatment in severe allergic asthma. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Real prevalence of severe asthma in developing countries – Is the diagnosis correct? Source: Virtual Congress 2020 – Clinical parameters in severe asthma Year: 2020 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Predicting treatment outcomes following an exacerbation of airways disease Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 The course of disease of patients who died from asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 217s Year: 2003 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Severe asthma outcomes over 18-months treatment with mepolizumab, and comorbidities in non-responders. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Predictors of asthma progressive course in patients with autoimmune thyroiditis Source: Eur Respir J 2007; 30: Suppl. 51, 554s Year: 2007 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007 Severe asthma outcomes over two years of therapy with mepolizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021